The BA.2 “stealth” omicron variant is expected to become the dominant strain soon. Here’s what you need to know about a possible new wave of infections. (Video: Brian Monroe, John Farrell / The Washington Post, Photo: The Washington Post) The results confirm what health officials and scientists have known for some time based on previous research. However, the study is important because vaccine efficacy data on real-world mixing and matching enhancement strategies were limited. The story goes on under the ad The new data, from a 10-state study conducted by independent researchers, may provide clarity amid a confused collection of data on the single-dose vaccine. It shows that three doses of a messenger RNA vaccine have the best performance, while a Johnson & Johnson vaccine followed by a booster RNA vaccine is the next best. Two Johnson & Johnson shots provide a lower level of protection, with just one shot being just 31% effective against hospitalization. “This is very low, especially in this world where we have access to other things,” said Natalie E. Dean, a biostatologist at Emory University Rollins School of Public Health. “One priority is to ensure that people who receive only one dose [of Johnson & Johnson vaccine] they know they have to go and preferably have a messenger RNA vaccine. “ The data also suggest a second boost with a messenger RNA vaccine, even for people who have received two doses of Johnson & Johnson, said Boghuma Titanji, an infectious disease specialist at Emory University. “This is not yet a formal recommendation,” Titanji said, “but it’s something that people in this category need to discuss with their healthcare provider.” The story goes on under the ad The takeaway: “If you can get the messenger RNA vaccine line, and especially get one as a souvenir, this [study] confirms that this is the way, “said Jeanne Marrazzo, director of the Department of Infectious Diseases at the University of Alabama at Birmingham. Experts say the latest CDC The study highlights what some experts say is a critical need for clearer recommendations for amplifiers. The story goes on under the ad “At the moment, there are no recommendations for people taking two doses of J&J to get a third messenger RNA vaccine,” said William Moss, executive director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health. (Those with moderate to severe immunosuppression are already advised to take a third dose.) “Messenger RNA vaccines seem to provide more protection… What I would like to see is a very simple recommendation: take all three doses and you should are messenger RNA vaccines. “ Several studies have shown that Pfizer and Moderna vaccines remain extremely effective in preventing the worst outcomes of infections, even when protection against less serious diseases has diminished over time. Although the Johnson & Johnson vaccine provides a lower level of initial protection than messenger RNA vaccines, the company has pointed out that its vaccine protection may not erode as quickly. The story goes on under the ad A study funded by Johnson & Johnson, which developed the vaccine and published in the JAMA Network Open, found that the effectiveness of the vaccine was stable over six months – 81 percent effective in preventing hospitalization, although it measured a period before the appearance of the omicron variant. “If there’s one thing we learned in the pandemic – and it’s not a new subject – the most informative work comes from people who are independent of the study,” said John P. Moore, professor of microbiology and immunology at Weill Cornell Medicine. . Moss said it was important for the public to keep in mind that the goal of vaccination is to prevent serious illness and death. But public messages became confused, he said, in part because early studies showed that messenger RNA vaccines provided protection against infection, raising “false expectations.” The story goes on under the ad It is natural for the levels of antibodies that fight viruses in the blood to decrease over time, Moss added. This is part of the design of the body’s immune response. “Otherwise our blood would be full of antibodies and [blood] “It could not flow… and supply oxygen to the cells,” he said. The CDC study analyzed data from more than 80,000 emergency or emergency care visits and more than 25,000 adult hospitalizations for Covid-19 in 10 states. from mid-December to 7 March, a period that includes the micron variation wave. When researchers compared the effectiveness of multiple vaccine combinations in preventing emergency or emergency care visits, they found: The story goes on under the ad · A shot of Johnson & Johnson offered 24 percent efficiency. · Two Johnson & Johnson shots offered 54 percent efficiency. A Johnson & Johnson combination with one Messenger messenger RNA amplifier offered 79 percent efficiency. Three messenger RNA downloads offered 83 percent efficiency. Hospitalization protection, meanwhile, was significantly higher with three doses of messenger RNA vaccines, which offered 90 percent efficacy. This compared to: A Johnson & Johnson shot, which offered 31 percent efficiency. · Two Johnson & Johnson shots, which offered 67 percent efficiency. A Johnson & Johnson vaccine with RNA messenger amplifier, which offered 78 percent effectiveness. The story goes on under the ad When the Food and Drug Administration approved the Johnson & Johnson vaccine in February 2021 for all adults, many believed that a one-size-fits-all approach would make it a tool for vaccinating the world. But last spring, federal officials stopped using the vaccine for 10 days and looked at reports of six cases of an extremely rare but potentially life-threatening blood clot among the millions of people who have received the vaccine in the United States. Vaccine use was subsequently reduced due to supply problems as well as concerns about coagulation. Nine deaths – between seven women and two men – have been confirmed in connection with the blood clot issue as of September. Seven of these patients, aged 28 to 62, had underlying conditions such as obesity, hypertension and diabetes. Carolyn Y. Johnson contributed to this report.
